FY2027 EPS Estimates for Intellia Therapeutics, Inc. (NASDAQ:NTLA) Decreased by Brookline Capital Management

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Stock analysts at Brookline Capital Management reduced their FY2027 earnings estimates for Intellia Therapeutics in a research note issued on Thursday, August 8th. Brookline Capital Management analyst L. Cann now expects that the company will post earnings per share of $22.05 for the year, down from their previous estimate of $22.39. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($4.98) per share. Brookline Capital Management also issued estimates for Intellia Therapeutics’ FY2028 earnings at $48.95 EPS.

Several other research firms have also recently issued reports on NTLA. Royal Bank of Canada reduced their target price on Intellia Therapeutics from $60.00 to $54.00 and set an “outperform” rating on the stock in a research note on Friday, August 9th. BMO Capital Markets upped their price objective on shares of Intellia Therapeutics from $62.00 to $70.00 and gave the stock an “outperform” rating in a report on Friday, May 10th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $73.00 target price on shares of Intellia Therapeutics in a research note on Thursday, June 27th. Truist Financial reissued a “buy” rating and issued a $120.00 price target on shares of Intellia Therapeutics in a research note on Monday, June 24th. Finally, StockNews.com raised Intellia Therapeutics to a “sell” rating in a research report on Thursday, June 27th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $61.58.

Intellia Therapeutics Price Performance

Shares of NASDAQ:NTLA opened at $22.41 on Monday. The stock’s 50-day moving average is $24.22 and its 200 day moving average is $25.25. The company has a market cap of $2.16 billion, a PE ratio of -4.11 and a beta of 1.81. Intellia Therapeutics has a 1 year low of $19.37 and a 1 year high of $39.14.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.29). The business had revenue of $7.00 million for the quarter, compared to analyst estimates of $19.68 million. The firm’s revenue was down 48.5% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.40) earnings per share.

Institutional Trading of Intellia Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Raymond James Financial Services Advisors Inc. boosted its holdings in Intellia Therapeutics by 13.3% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 36,225 shares of the company’s stock worth $1,104,000 after acquiring an additional 4,255 shares in the last quarter. Arizona State Retirement System boosted its stake in Intellia Therapeutics by 4.0% in the 4th quarter. Arizona State Retirement System now owns 23,500 shares of the company’s stock worth $717,000 after purchasing an additional 914 shares in the last quarter. International Assets Investment Management LLC purchased a new stake in Intellia Therapeutics during the 4th quarter valued at about $715,000. DekaBank Deutsche Girozentrale increased its stake in Intellia Therapeutics by 47.1% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 78,129 shares of the company’s stock valued at $2,497,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its holdings in Intellia Therapeutics by 7.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 8,144 shares of the company’s stock worth $248,000 after buying an additional 582 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.